

# ***Shivani Satish Wagh***

A-501, Venus Vasant Valley, Filmcity Road, Malad (East), Mumbai – 400097

**March 12, 2024**

To,  
**Securities and Exchange Board of India**  
Plot No. C4-A, 'G' Block,  
Bandra Kurla Complex, Bandra East,  
Mumbai – 400051, Maharashtra.

**Sub: Report under Regulation 10(7) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.**

**Dear Sir/Madam,**

Please find enclosed herewith the copy of the Report under Regulation 10(7) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 in respect of acquisition of 73,125 equity shares of Supriya Lifescience Limited from Dr. Saloni Wagh.

This is for your kind information and record.

Thanking you,

Yours faithfully,

**Shivani Wagh**  
**Acquirer**

Encl: As above

**CC:**

**1. BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai  
**Scrip Code - 543434**

**2. National Stock Exchange of India Ltd**  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G block,  
Bandra-Kurla Complex,  
Bandra (E),  
Mumbai – 400 051  
**Scrip ID – SUPRIYA**

**3. The Company Secretary**  
**Supriya Lifescience Limited**  
207/208, Udyog Bhavan,  
Sonawala Road, Goregaon  
(East), Mumbai – 400063.

**Regulation 10(7) – Report to SEBI in respect of any acquisition made in reliance upon exemption provided for in regulation 10(1)(a)(i) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

<b>1</b>	<b>General Details</b>	
	a. Name, address, telephone no., e-mail of acquirer(s) {In case there are multiple acquirers, provide full contact details of any one acquirer (the correspondent acquirer) with whom SEBI shall correspond.}	Shivani Wagh Address: A-501, Venus Vasant Valley, Filmcity Road, Malad (East), Mumbai – 400097. Telephone No.: 022 40332727 Email: <a href="mailto:shivani@supriyalifescience.com">shivani@supriyalifescience.com</a>
	b. Whether sender is the acquirer (Y/N)	Yes
	c. If not, whether the sender is duly authorized by the acquirer to act on his behalf in this regard (enclose copy of such authorization)	NA
	d. Name, address, Tel no. and e-mail of the sender, if sender is not the acquirer	NA
<b>2</b>	<b>Compliance of Regulation 10(7)</b>	
	a. Date of report	12.03.2024
	b. Whether report has been submitted to SEBI within 21 working days from the date of the acquisition	Yes, the report has been submitted within 21 working days from the date of acquisition.
	c. Whether the report is accompanied with fees as required under Regulation 10(7)	Yes, the details are enclosed herewith.
<b>3</b>	<b>Compliance of Regulation 10(5)</b>	
	a. Whether the report has been filed with the Stock Exchanges where the shares of the Company are listed, atleast 4 working days before the date of the proposed acquisition	Yes
	b. Date of Report	19.12.2023
<b>4</b>	<b>Compliance of Regulation 10(6)</b>	
	a. Whether the report has been filed with the Stock Exchanges where the shares of the Company are listed within 4 working days after the date of the proposed acquisition	Yes
	b. Date of Report	28.02.2024
<b>5</b>	<b>Details of the Target Company (TC)</b>	
	a. Name & address of TC	Supriya Lifescience Limited Regd. Office: 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063.

	b.	Name of the Stock Exchange(s) where the shares of the TC are listed	National Stock Exchange of India Limited BSE Limited			
<b>6</b>	<b>Details of the acquisition</b>					
	a.	Date of acquisition	26.02.2024			
	b.	Acquisition price per share (in Rs.)	Not applicable {Inter-se transfer of shares by way of Gift between member of promoter group (immediate relative)}.			
	c.	Regulation which would have been triggered an open offer, had the report not been filed under Regulation 10(7). (whether Regulation 3(1), 3(2), 4 or 5)	Regulation 3(2)			
	d.	Shareholding of acquirer(s) and PAC individually in TC (in terms of no. & as a percentage of the total share/voting capital of the TC)(*)	Before the acquisition		After the acquisition	
			No. of Shares	% w.r.t total share capital of TC	No. of Shares	% w.r.t total share capital of TC
		Name of the acquirer(s) / PAC (**)	Please refer to the Annexure - 1			
	e.	Shareholding of seller/s in TC (in terms of no. & as a percentage of the total share/voting capital of the TC)	Before the acquisition		After the acquisition	
			No. of Shares	% w.r.t total share capital of TC	No. of Shares	% w.r.t total share capital of TC
		Name of the Seller(s)(**)	Please refer to the Annexure - 1			
<b>7</b>	<b>Information specific to the exemption category to which the instant acquisition belongs-Regulation 10(1)(a)(i)</b>					
	a.	Provide the names of the seller(s)	Dr. Saloni Wagh, member of Promoter Group			
	b.	Specify the relationship between the acquirer(s) and the seller(s).	Ms. Shivani Wagh is the sister of Dr. Saloni Wagh.  Hence, they are immediate relatives of each other and also member of promoter group.			
	c.	Confirm whether the acquirer(s) and the seller(s) are 'immediate relatives' as defined in the Regulation 2(1).	Yes, the acquirer and the seller fall under the definition of immediate relatives stated under Regulation 2(1) of the SAST Regulations.			
	d.	If shares of the TC are frequently traded, volume-weighted average market price (VWAP) of such shares for a period of sixty trading days preceding the date of issuance of notice regarding the proposed acquisition to the stock exchanges where the TC is listed.	Not Applicable. The shares were transferred by way of Gift. Therefore, no consideration was involved.			

e.	If the shares of the TC are infrequently traded, the price of such shares as determined in terms of clause (e) of sub-regulation (2) of regulation 8.	Not Applicable. The shares were transferred by way of Gift. Therefore, no consideration was involved.
f.	Confirm whether the acquisition price per share is not higher by more than twenty-five percent of the price as calculated in (d) or (e) above as applicable.	Not Applicable. The shares were transferred by way of Gift. Therefore, no consideration was involved.
g.	Date of issuance of notice regarding the proposed acquisition to the stock exchanges where the TC is listed.	19.12.2023
h.	Whether the acquirers as well as sellers have complied with the provisions of Chapter V of the Takeover Regulations (corresponding provisions of the repealed Takeover Regulations 1997) (Y/N). If yes, specify applicable regulation(s) as well as date on which the requisite disclosures were made along with the copies of the same.	Yes, the acquirer as well as seller have complied with the provisions of Chapter V of the Takeover Regulations, 2011.  The disclosure filed under Regulation 29(2) on 27.02.2024 is enclosed herewith for the current transaction.
i.	Declaration by the acquirer that all the conditions specified under regulation 10(1)(a)(i) with respect to exemptions has been duly complied with.	I hereby confirmed that all the conditions specified under Regulation 10(1)(a)(i) with respect to exemptions has been duly complied with.  Such declaration was given along with the report under Regulation 10(6) to the Stock Exchanges 28.02.2024.

I/We hereby declare that the information provided in the instant report is true and nothing has been concealed there from.

Signature:

**Shivani Wagh**  
**Date: 12.03.2024**

**NOTE:**

(\*) In case, percentage of shareholding to the total capital is different from percentage of voting rights, indicate percentage of shareholding and voting rights separately.

(\*\*) Shareholding of each entity shall be shown separately and then collectively in a group.

**Annexure- 1**

Shareholding details		Before the acquisition		After the acquisition	
		No. of Shares	% w.r.t total share capital of TC	No. of Shares	% w.r.t total share capital of TC
	<b>Name of the acquirer(s) / PAC</b>				
<b>a.</b>	<b>Name of the acquirer</b>				
	Shivani Satish Wagh	29,250	0.04	1,02,375	0.13
<b>b.</b>	<b>Name of the PACs (other than Seller)</b>				
	Satish Waman Wagh	5,44,41,205	67.64	5,44,41,205	67.64
	Smita Satish Wagh	3,21,750	0.40	3,21,750	0.40
	Supriya Pharmaceuticals	10	0.00	10	0.00
<b>c.</b>	<b>Name of the seller:</b>				
	Saloni Satish Wagh	1,75,500	0.22	1,02,375	0.13
	<b>Total (a+b+c)</b>	<b>54967715</b>	<b>68.30</b>	<b>54967715</b>	<b>68.30</b>





# ***Shivani Satish Wagh***

---

**February 27, 2024**

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001  
**Scrip Code - 543434**

To,  
**National Stock Exchange of India Ltd**  
Exchange Plaza, Plot No. C/1, G block,  
Bandra-Kurla Complex,  
Bandra (E), Mumbai – 400 051  
**Scrip ID – SUPRIYA**

**Sub.: Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.**

**Dear Sir / Madam,**

Please find attached herewith the disclosure under the Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, in connection with the inter-se-transfer of 73,125 equity shares in off market transaction by way of gift from Dr. Saloni Satish Wagh to Ms. Shivani Satish Wagh.

This is for your kind information and record.

Thanking you,

Yours faithfully,

  
**Shivani Satish Wagh**  
**Acquirer & member of Promoter Group**

Encl: As above

**CC:**  
**The Company Secretary**  
**Supriya Lifescience Limited**  
207/208, Udyog Bhavan, Sonawala Road,  
Goregaon (East), Mumbai – 400 063.



**Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

Name of the Target Company (TC)	Supriya Lifescience Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	<b>Acquirer:</b> Shivani Satish Wagh  <b>Person Acting in Concert (PAC):</b> Dr. Satish Waman Wagh Mrs. Smita Satish Wagh Dr. Saloni Satish Wagh Supriya Pharmaceuticals		
Whether the acquirer belongs to Promoter/ Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1. BSE Limited 2. National Stock Exchange of India Limited		
Details of the acquisition/ <del>Disposal</del> as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
<b>Before the acquisition under consideration, holding of:</b>			
a) Shares carrying voting rights			
<b>Seller:</b>			
Dr. Saloni Satish Wagh	1,75,500	0.22	0.22
<b>Acquirer:</b>			
Ms. Shivani Satish Wagh	29,250	0.04	0.04
<b>Person Acting in Concert (PAC):</b>			
Dr. Satish Waman Wagh	5,44,41,205	67.64	67.64
Mrs. Smita Satish Wagh	3,21,750	0.40	0.40
Supriya Pharmaceuticals	10	0.00	0.00
b) Shares in the nature of encumbrance (pledge/lien/ non-disposal undertaking/ others)			
c) Voting rights (VR) otherwise than by equity shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)			
e) Total (a+b+c+d)	<b>5,49,67,715</b>	<b>68.30</b>	<b>68.30</b>

<b>Details of acquisition/sale</b>			
a) Shares carrying voting rights acquired/sold <b>Seller:</b> Dr. Saloni Satish Wagh	(73,125)	(0.09)	(0.09)
<b>Shares carrying voting rights acquired:</b> Ms. Shivani Satish Wagh	73,125	0.09	0.09
b) VRs acquired otherwise than by shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold			
d) Shares encumbered / invoked/released by the acquirer			
e) Total (a+b+c+d)	-	-	-
<b>After the acquisition/sale, holding of:</b>			
a) Shares carrying voting rights <b>Seller:</b> Dr. Saloni Satish Wagh	1,02,375	0.13	0.13
<b>Acquirer:</b> Ms. Shivani Satish Wagh	1,02,375	0.13	0.13
<b>Person Acting in Concern (PAC):</b> Dr. Satish Waman Wagh	5,44,41,205	67.64	67.64
Mrs. Smita Satish Wagh	3,21,750	0.40	0.40
Supriya Pharmaceuticals	10	0.00	0.00
b) Shares encumbered with the acquirer			
c) VRs otherwise than by shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition			
e) Total (a+b+c+d)	<b>5,49,67,715</b>	<b>68.30</b>	<b>68.30</b>
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Off market Inter-se transfer of shares in the form of a gift		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable.	26/02/2024		
Equity share capital / total voting capital of the TC before the said acquisition / sale.	Equity Share Capital of Rs.16,09,65,600 consisting of 8,04,82,800 Equity Shares of Rs.2/- each		
Equity share capital/ total voting capital of the TC after the said acquisition / sale.	Equity Share Capital of Rs.16,09,65,600 consisting of 8,04,82,800 Equity Shares of Rs.2/- each		




Total diluted share/voting capital of the TC after the said acquisition.

Equity Share Capital of Rs.16,09,65,600 consisting of 8,04,82,800 Equity Shares of Rs.2/- each

*(\*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Regulation 31 of the SEBI LODR.*

*(\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.*

**Shivani Satish Wagh**



**Acquirer**

**Date: February 27, 2024**

**Place: Mumbai**

# ***Shivani Satish Wagh***

---

**February 28, 2024**

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001  
**Scrip Code - 543434**

To,  
**National Stock Exchange of India Ltd**  
Exchange Plaza, Plot No. C/1, G block,  
Bandra-Kurla Complex,  
Bandra (E), Mumbai – 400 051  
**Scrip ID – SUPRIYA**

**Sub: Disclosure under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.**

**Ref.: Prior intimation submitted under Regulation 10(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 dated December 19, 2023.**

**Dear Sir / Madam,**


With regard to the captioned subject and in continuation to my prior intimation submitted under Regulation 10(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 dated December 19, 2023, please find enclosed herewith the disclosure under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 with respect to the acquisition of 73,125 (Seventy Three Thousand One Hundred and Twenty-Five) equity shares of Supriya Lifescience Limited (Target Company) from Dr. Saloni Satish Wagh, member of Promoter group Whole Time Director of Target Company, details of which are enclosed herewith.

The said acquisition is pursuant to off market inter-se transfer of shares between member of Promoter Group (immediate relatives), as specified in Regulation 10(1)(a)(i) and (ii) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 by way of Gift.

This is for your kind information and record.

Thanking you,

Yours faithfully,

  
**Shivani Satish Wagh**  
**Acquirer & member of Promoter Group**

Encl: As above

**CC:**  
**The Company Secretary**  
**Supriya Lifescience Limited**  
207/208, Udyog Bhavan, Sonawala Road,  
Goregaon (East), Mumbai – 400 063.



Disclosures under Regulation 10(6) –Report to Stock Exchanges in respect of any acquisition made in reliance upon exemption provided for in Regulation 10 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011			
1.	Name of the Target Company (TC)	Supriya Lifescience Limited	
2.	Name of the acquirer(s)	Shivani Satish Wagh	
3.	Name of the stock exchange where shares of the TC are listed	1. BSE Limited 2. National Stock Exchange of India Limited	
4.	Details of the transaction including rationale, if any, for the transfer/ acquisition of shares.	Transfer of 73,125 Equity Shares i.e. 0.09% of total share capital as per the latest shareholding pattern of the TC from Dr. Saloni Satish Wagh to Ms. Shivnai Satish Wagh. (Ms. Shivnai Satish Wagh is the sister of Dr. Saloni Satish Wagh).  Inter-se transfer of shares amongst member of Promoter Group (immediate relatives) without consideration by way of Gift.	
5.	Relevant regulation under which the acquirer is exempted from making open offer.	Under Regulation 10(1)(a)(i) and (ii) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011	
6.	Whether disclosure of proposed acquisition was required to be made under regulation 10 (5) and if so, - whether disclosure was made and whether it was made within the timeline specified under the regulations. - date of filing with the stock exchange.	The proposed acquisition was made under regulation 10 (5) - Intimation to Stock Exchanges in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Yes, the disclosure was made within the timeline specified under the regulations. The same was filed on 19.12.2023 with stock exchanges.	
7.	Details of acquisition	Disclosures required to be made under regulation 10(5)	Whether the disclosures under regulation 10(5) are actually made
a.	Name of the transferor / seller	Dr. Saloni Satish Wagh	Yes
b.	Date of acquisition	26.02.2024	Yes
c.	Number of shares/ voting rights in respect of the acquisitions from each person mentioned in 7(a) above	73,125	Yes
d.	Total shares proposed to be acquired / actually acquired as a % of diluted share capital of TC	0.09% of total share capital as per the latest shareholding pattern of the TC	Yes
e.	Price at which shares are proposed to be acquired / actually acquired	Not Applicable (Inter se transfer of shares among the Promoter Group without consideration by way of Gift)	Yes

8.	Shareholding details	Pre-Transaction		Post-Transaction	
		No. of shares held	% w.r.t total share capital of TC	No. of shares held	% w.r.t total share capital of TC
	a Each Acquirer / Transferee(*) along with PAC				
	Ms. Shivani Satish Wagh	29,250	0.04	1,02,375	0.13
	Dr. Satish Waman Wagh	5,44,41,205	67.64	5,44,41,205	67.64
	Mrs. Smita Satish Wagh	3,21,750	0.40	3,21,750	0.40
	Supriya Pharmaceuticals	10	0.00	10	0.00
	b Each Seller / Transferor				
	Dr. Saloni Satish Wagh	1,75,500	0.22	1,02,375	0.13
	<b>Total</b>	<b>5,49,67,715</b>	<b>68.30</b>	<b>5,49,67,715</b>	<b>68.30</b>

Note:

(\*) Shareholding of each entity shall be shown separately and then collectively in a group.

The above disclosure shall be signed by the acquirer mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by a person duly authorized to do so on behalf of all the acquirers.

\*\*\*\*\*



Shivani Wagh  
Acquirer



# ***Shivani Satish Wagh***

---

**February 27, 2024**

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001  
**Scrip Code - 543434**

To,  
**National Stock Exchange of India Ltd**  
Exchange Plaza, Plot No. C/1, G block,  
Bandra-Kurla Complex,  
Bandra (E), Mumbai – 400 051  
**Scrip ID – SUPRIYA**

**Sub.: Disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.**


**Dear Sir / Madam,**

Please find attached herewith the disclosure under the Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, in connection with the inter-se-transfer of 73,125 equity shares in off market transaction by way of gift from Dr. Saloni Satish Wagh to Ms. Shivani Satish Wagh.

This is for your kind information and record.

Thanking you,

Yours faithfully,

  
**Shivani Satish Wagh**  
**Acquirer & Member of Promoter Group**

Encl: As above

**CC:**  
**The Company Secretary**  
**Supriya Lifescience Limited**  
207/208, Udyog Bhavan, Sonawala Road,  
Goregaon (East), Mumbai – 400063.

**Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

**Part-A- Details of the Acquisition**


Name of the Target Company (TC)	Supriya Lifescience Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	<b>Acquirer:</b> Shivani Satish Wagh  <b>Person Acting in Concert (PAC):</b> Dr. Satish Waman Wagh Mrs. Smita Satish Wagh Dr. Saloni Satish Wagh Supriya Pharmaceuticals		
Whether the acquirer belongs to Promoter/ Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1. BSE Limited 2. National Stock Exchange of India Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
<b>Before the acquisition under consideration, holding of acquirer along with PACs:</b>			
a) Shares carrying voting rights			
<b>Acquirer:</b> Shivani Satish Wagh	29,250	0.04	0.04
<b>Person Acting in Concert (PAC):</b>			
Dr. Satish Waman Wagh	5,44,41,205	67.64	67.64
Mrs. Smita Satish Wagh	3,21,750	0.40	0.40
Dr. Saloni Satish Wagh	1,75,500	0.22	0.22
Supriya Pharmaceuticals	10	0.00	0.00
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
c) Voting rights (VR) otherwise than by equity shares			



d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)			
e) Total (a+b+c+d)	<b>5,49,67,715</b>	<b>68.30</b>	<b>68.30</b>
<b>Details of acquisition:</b>			
a) Shares carrying voting rights acquired			
Shivani Satish Wagh	73,125	0.09	0.09
b) VRs acquired otherwise than by shares			
c) Warrants/ convertible securities/ any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/ sold			
d) Shares encumbered / invoked/ released by the acquirer			
e) Total (a+b+c+d)	<b>73,125</b>	<b>0.09</b>	<b>0.09</b>
<b>After the acquisition holding of acquirer along with PACs of:</b>			
a) Shares carrying voting rights			
<b>Acquirer:</b>			
Shivani Satish Wagh	1,02,375	0.13	0.13
<b>Person Acting in Concern (PAC):</b>			
Dr. Satish Waman Wagh	5,44,41,205	67.64	67.64
Mrs. Smita Satish Wagh	3,21,750	0.40	0.40
Dr. Saloni Satish Wagh	1,02,375	0.13	0.13
Supriya Pharmaceuticals	10	0.00	0.00
b) VRs otherwise than by shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition			
d) Shares in the nature of encumbrance (pledge/ lien/non-disposal undertaking/ others)			
e) Total (a+b+c+d)	<b>5,49,67,715</b>	<b>68.30</b>	<b>68.30</b>
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Off market Inter-se transfer of shares in the form of a gift		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	The acquired Equity Shares shall rank pari-passu with the existing Equity Shares of the Company.		

Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	26/02/2024
Equity share capital / total voting capital of the TC before the said acquisition / sale.	Equity Share Capital of Rs.16,09,65,600 consisting of 8,04,82,800 Equity Shares of Rs.2/- each
Equity share capital/ total voting capital of the TC after the said acquisition / sale.	Equity Share Capital of Rs.16,09,65,600 consisting of 8,04,82,800 Equity Shares of Rs.2/- each
Total diluted share/voting capital of the TC after the said acquisition.	Equity Share Capital of Rs.16,09,65,600 consisting of 8,04,82,800 Equity Shares of Rs.2/- each

**Shivani Satish Wagh**



Acquirer

**Date: February 27, 2024**

**Place: Mumbai**

**Part-B\*\***


**Name of the Target Company: Supriya Lifescience Limited**

*(\* Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Regulation 31 of the SEBI LODR.*

*(\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.*

*(\*\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated..*

**Shivani Satish Wagh**



**Acquirer**

**Date: February 27, 2024**

**Place: Mumbai**



**December 19, 2023**

To,  
**BSE Limited**  
1<sup>st</sup> Floor,  
New Trading Ring,  
Rotunda Building,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai  
**Scrip Code - 543434**

To,  
**National Stock Exchange of India Ltd**  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G block,  
Bandra-Kurla Complex,  
Bandra (E),  
Mumbai – 400 051  
**Scrip ID – SUPRIYA**

**Sub: Submission of disclosure required under Regulation 10(5) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

**Dear Sir/Madam,**

I hereby submit the disclosure under Regulation 10(5) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for acquisition of 73,125 (Seventy-Three Thousand One hundred and Twenty-Five) shares of Supriya Lifescience Limited from Dr. Saloni Satish Wagh (Sister and forming part of Promoter group), details of which are enclosed herewith as Annexure 1.


Please note that this transaction, being inter-se transfer of shares amongst the immediate relatives and Promoter Group, falls within the exemptions provided under Regulation 10(1)(a)(i) and (ii) of the SEBI (SAST) Regulations, 2011.

The Aggregate holding of promoter & promoter group before and after the above inter-se transaction will remain the same.

This is for your kind information and record.

Thanking you,

Yours faithfully,

  
**Shivani Satish Wagh**  
Acquirer and member of Promoter Group

Date: December 19, 2023

Place: Mumbai

Encl: As above

**CC: Supriya Lifescience Limited**

207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400063.

**Annexure 1**

**Format for Disclosures under Regulation 10(5) – Intimation to Stock Exchanges in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

1.	Name of the Target Company (TC)	Supriya Lifescience Limited
2.	Name of the acquirer(s)	Shivani Satish Wagh
3.	Whether the acquirer(s) is/ are promoters of the TC prior to the transaction. If not, nature of relationship or association with the TC or its promoters	Yes
4.	Details of the proposed acquisition	
	a. Name of the person(s) from whom shares are to be acquired	Dr. Saloni Satish Wagh
	b. Proposed date of acquisition	On or After 27.12.2023
	c. Number of shares to be acquired from each person mentioned in 4(a) above	73,125 Equity Shares
	d. Total shares to be acquired as % of share capital of TC	0.09 % of total share capital as per the latest shareholding pattern of the Company.
	e. Price at which shares are proposed to be acquired	Not Applicable (Inter se transfer of shares among the Promoter Group without consideration by way of Gift)
	f. Rationale, if any, for the proposed transfer	Inter-se transfer of shares amongst Promoter Group without consideration
5.	Relevant sub-clause of regulation 10(1)(a) under which the acquirer is exempted from making open offer	Under Regulation 10(1)(a)(i) and (ii) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
6.	If, frequently traded, volume weighted average market price for a period of 60 trading days preceding the date of issuance of this notice as traded on the stock exchange where the maximum volume of trading in the shares of the TC are recorded during such period.	NA
7.	If in-frequently traded, the price as determined in terms of clause (e) of sub-regulation (2) of regulation 8.	NA
8.	Declaration by the acquirer, that the acquisition price would not be higher by more than 25% of the price computed in point 6 or point 7 as applicable.	Not Applicable since proposed transfer is by way of gift, hence, acquisition price is zero





9.	Declaration by the acquirer, that the transferor and transferee have complied / will comply with applicable disclosure requirements in Chapter V of the Takeover Regulations, 2011 (corresponding provisions of the repealed Takeover Regulations 1997)	Yes, I , Ms. Shivani Satish Wagh ('the acquirer'), hereby declare that the transferor (Dr. Saloni Satish Wagh) and transferee have complied/ will comply with all applicable disclosure requirements in Chapter V of the Takeover Regulations, 2011.
10.	Declaration by the acquirer that all the conditions specified under regulation 10(1)(a) with respect to exemptions has been duly complied with.	Yes, all the conditions specified under regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 with respect exemptions has been duly complied with.

11.	Shareholding details	Before the proposed transaction		After the proposed transaction	
		No. of shares /voting rights	% w.r.t total share capital of TC	No. of shares /voting rights	% w.r.t total share capital of TC
a	Acquirer(s) and PACs (other than sellers) (*)				
	Shivani Satish Wagh	29,250	0.04	1,02,375	0.13
	Satish Waman Wagh	5,44,41,205	67.64	5,44,41,205	67.64
	Smita Satish Wagh	3,21,750	0.40	3,21,750	0.40
	Supriya Pharmaceuticals	10	0.00	10	0.00
b	Seller (s)	1,75,500	0.22	1,02,375	0.13

**Note:**

(\*) Shareholding of each entity may be shown separately and then collectively in a group. The above disclosure shall be signed by the acquirer mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by a person duly authorized to do so on behalf of all the acquirers.